In re Appln. of Kiesewetter et al. Serial No. Unassigned

Use of the ribonucleotide proteins according to claim 2 and/or molecular-biological equivalent structures and/or fragments and/or derivatives for producing a medicament for specifically influencing angiogenesis.

1. Use of the ribonuclectide proteins according to claim 3 and/or molecular-biological equivalent structures and/or fragments and/or derivatives for producing a medicament for specifically influencing angiogenesis.

REMARKS

The claims have been amended in order to place the claims in a format more suitable to U.S. patent practice. No new matter has been added by way of these amendments. The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,

Salim A. Hasan, Reg No. 38,175

One of the Attorneys for Applicant(s)

LEYDIG, VOIT & MAYER, LTD.

Two Prudential Plaza, Suite 4900

180 North Stetson

Chicago, Illinois 60601-6780

(312) 616-5600 (telephone)

(312) 616-5700 (facsimile)

Date: September 13, 2000